AstraZeneca Partners with Revna Biosciences to Enhance Epidermal Growth Factor Receptor (EGFR) Biomarker Testing in Ghana
EGFR Testing
Epidermal Growth Factor Receptor (EGFR) is a protein involved in cell growth, division and survival. Mutations in the EGFR gene lead to the over-production of EGFR proteins on some types of cancer cells, causing the cells to divide more rapidly.
EGFR is regarded as the cancer driver gene in lung cancer, particularly non-small cell lung cancer (NSCLC), and serves as a biomarker in cancer treatment. Accurate testing for EGFR mutations allows doctors to determine the best course of treatment for patients, including the use of targeted therapies that have shown greater efficacy and fewer side effects than traditional chemotherapy.
Today's Patient, Tomorrow's Hope
Dr. Khomotso Mashilane, Medical Director African Cluster at AstraZeneca remarked on the program's potential impact: 'At AstraZeneca, we are committed to working collaboratively with governments, healthcare professionals, and patient communities to create resilient healthcare systems and expand access to innovative cancer treatments for patients across Africa. By investing in EGFR biomarker testing and precision medicine, we are taking a pivotal step toward giving patients in Ghana the treatments they need and deserve. Today's patients are at the heart of our work, and with tomorrow's advances in targeted therapies, we are confident that hope will become a tangible reality for many.'
The first step in this collaboration is to map and streamline the patient journey from accurate diagnosis through treatment for improved health outcomes. Beyond providing advanced biomarker testing resource, this partnership will offer educational programs and workshops to equip healthcare professionals in the lung cancer space with next-generation tools, aiming for earlier detection and better clinical outcomes, ultimately contributing to global cancer control.
We anticipate initiating the rollout process shortly, which will encompass onboarding of participating healthcare professionals, the commencement of the first series of workshops, and participant selection.
Future Look
Dr. Derrick Edem Akpalu, CEO and Co-Founder of Revna Biosciences also spoke about the importance of the partnership 'This collaboration is timely, as the demand for personalized healthcare is growing. Advances in EGFR testing and targeted therapies offer unprecedented hope for improved cancer care in Ghana. Together, we aim to raise awareness and increase access to life-saving treatments, ensuring that every patient in Ghana has the best chance to thrive. The knowledge we gain today will help shape a better tomorrow for patients here and around the world."
Distributed by APO Group on behalf of Revna Biosciences.
About AstraZeneca:
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. The business is organized to deliver growth through innovation strategy and achieve the purpose of pushing the boundaries of science to deliver life-changing medicines in oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases.
Inspired by values and what science can do, AstraZeneca is focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society and shareholders. They are committed to operating sustainably, in a way that recognizes the interconnection between business growth, the needs of society and the limitations of the planet.
About Revna Biosciences:
With an operational base in Accra, Ghana, and serving across West Africa, Revna Biosciences (RevnaBio) is a biomedical company committed to advancing molecular diagnostics and therapeutic discovery. With a mission to champion precision medicine for all, RevnaBio is devoted to unraveling the biological underpinnings of diseases affecting Africans, people of African descent, and the global population.
RevnaBio offers a comprehensive suite of services, including advanced molecular diagnostics, biobanking, biomarker exploration, clinical research, central lab services, disease monitoring, treatment selection, and trial management. Through strategic alliances with international biotech leaders such as QIAGEN, Diatech Pharmacogenetics, ABL Diagnostics, and Idil Biotech, RevnaBio delivers cutting-edge biomedical services in the heart of West Africa.
RevnaBio holds all necessary local permits and licenses, including the Health Facilities Regulatory Authority (HeFRA) permit for tertiary laboratories. RevnaBio has the approval of Ghana's Food&Drugs Authority (FDA), is dual ISO accredited (ISO 15189:2022; ISO 20387:2018) by the American Association for Laboratory Accreditation (A2LA) and a member of the International Society of Biological and Environmental Repositories (ISBER).
For more information about Revna Biosciences and its groundbreaking work in precision medicine, please contact +233-59-900-9977 or visit www.RevnaBio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
01-08-2025
- Zawya
AstraZeneca enters rare disease care in South Africa
AstraZeneca announced its entrance into rare disease care in South Africa at a launch event held at the Nelson Mandela Children's Hospital in Johannesburg. Its rare disease portfolio will bring treatments for complex conditions such as neurofibromatosis type 1 (NF1), paroxysmal nocturnal hemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS), and myasthenia gravis. The event included a panel discussion with experts from fields such as neuro-oncology, neurology, plastic surgery, and genetics. Panellists highlighted the vital need for coordinated, specialist-driven care and robust collaboration across public and private sectors to ensure that patients receive integrated support at every stage of their journey. Dr Nkuli Boikhutso, CEO of Nelson Mandela Children's Hospital, stated: 'We are honoured to be the site of this important milestone. "AstraZeneca's commitment to introducing new treatments for rare diseases offers hope for our young patients and aligns with our vision to provide world-class, specialised care for all children, regardless of their background.' Rare diseases Around the world, more than 400 million people are affected by over 10,000 known rare diseases, yet the vast majority of these conditions have no approved treatments. For many rare disease patients and their families, this often results in years of uncertainty, misdiagnosis, and limited or difficult treatment options. AstraZeneca is dedicated to transforming this landscape by introducing advanced therapies, supporting earlier and more accurate diagnoses, and fostering multidisciplinary collaboration. 'AstraZeneca's entry into the rare disease space in South Africa is both a proud and hopeful moment for us,' said Deepak Arora, African cluster country president at AstraZeneca. 'Building on decades of pioneering rare disease science, we are committed to expanding access to transformational medicines for conditions such as NF1, PNH. 'This marks a significant milestone in our mission to improve the lives of patients living with rare diseases, especially children who have had very few options until now.' AstraZeneca's rare disease strategy in Africa is anchored in three key priorities: accelerating access to vital medicines, driving innovation through research and development, and expanding its global reach to make meaningful change. All rights reserved. © 2022. Provided by SyndiGate Media Inc. (
Gulf Today
23-07-2025
- Gulf Today
AstraZeneca plans to invest $50 billion in US by 2030
AstraZeneca has announced a $50 billion investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country, powering growth and delivering next-generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production. The $50 billion investment across the company's R&D and manufacturing footprint in the US over the next five years also includes expanding the R&D facility in Gaithersburg, Maryland; building a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; establishing manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continue manufacturing expansion in Mount Vernon, Indiana; and expanding the specialty manufacturing in Coppell, Texas. WAM
Al Etihad
22-07-2025
- Al Etihad
AstraZeneca says to invest $50 billion in the US
22 July 2025 11:25 LONDON (AFP)British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States amid a looming deadline of ramped-up tariffs from Washington.A large chunk of the funds will go toward building a multi-billion-dollar manufacturing centre in Virginia, the company said in a statement, adding that it expects 50 percent of its revenue to come from the United States by 2030."Today's announcement underpins our belief in America's innovation in biopharmaceuticals," the statement quoted CEO Pascal Soriot as President Donald Trump has opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to his sweeping levies on imports from trading ordered an investigation launched into pharmaceutical imports, suggesting that levies could reach up to 200 United States is a key market for the pharmaceutical industry, and AstraZeneca had already announced in April that it had begun transferring part of its European production to the United States. "For decades Americans have been reliant on foreign supply of key pharmaceutical products," US Commerce Secretary Howard Lutnick said in a added that the new tariffs are focused on "ending this structural weakness."The announcement included a new factory in Virginia, which will be the company's "largest single manufacturing investment." Other major pharmaceutical companies, which had been exempt from tariffs for 30 years, have, in recent months, begun shifting investment and production to the United States.
